Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Symphony reports consistent trading as it works to accelerate projects

(Sharecast News) - Symphony Environmental Technologies said in an update on Friday that its trading remained consistent with recent statements. The AIM-traded firm, which was holding its annual general meeting, said it was actively working on accelerating the commercialisation of several projects, while continuing to refine costs.

"I would like to re-emphasise that many of these opportunities are significant and with continuing positive conversations, trials and other factors, the board have confidence that these will be converted in the short to medium term," said chairman Nicolas Clavel.

"The 2024 outlook, and beyond, is showing a positive commercial position for the group and pleasingly is across all of our main d2w and d2p technology offerings.

"In summary therefore, having recently raised equity to strengthen the balance sheet and with positive progress being made with our host of pipeline projects, the board looks to the future with optimism."

At 1140 BST, shares in Symphony Environmental Technologies were up 8.49% at 2.88p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Ethernity secures $1.05m licence agreement
(Sharecast News) - Data processing semiconductor technology specialist Ethernity Networks announced on Friday that it had secured a $1.05m licence agreement with a new tier one US-based aerospace system products provider.
Mirriad flags weaker first-half revenue
(Sharecast News) - Virtual product placement and in-content advertising specialist Mirriad said in an update on Friday that it expected revenue for the first half to be around £0.4m, down from £0.59m in the first six months of the 2023 financial year.
European drugs body backs Moderna jab
(Sharecast News) - Europe's drug regulator has backed Moderna's novel vaccine for respiratory syncytial virus, the US pharmaceutical firm announced on Friday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.